 |
 Video: What is a Stock Split?
|
|
|
| BioCardia is a clinical-stage company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Co.'s CardiAMP® autologous mononuclear cell therapy platform is being developed for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Co.'s neurokinin-1 receptor positive allogeneic mesenchymal stem cell therapy platform is being developed as an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF and for acute respiratory distress syndrome. According to our BioCardia stock split history records, BioCardia has had 0 splits. | |
|
BioCardia (BCDA) has 0 splits in our BioCardia stock split history database.
Looking at the BioCardia stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BioCardia shares, starting with a $10,000 purchase of BCDA, presented on a split-history-adjusted basis factoring in the complete BioCardia stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2014 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$0.08 |
|
| End price/share: |
$0.37 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
362.50% |
|
| Average Annual Total Return: |
16.55% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$46,231.77 |
|
| Years: |
10.00 |
|
|
|
|
|
